Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours By Ogkologos - February 17, 2026 128 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DELII study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of... May 5, 2025 Παρακολούθηση και Φροντίδα January 14, 2019 Cancer Research UK releases 2022 gender and ethnicity pay gap reports March 23, 2023 Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors... August 5, 2022 Load more HOT NEWS Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Multiple... 2-Year-Old Cancer Survivor With Down Syndrome Hears For First Time: ‘Her... New Generation of Antibody-Drug Conjugates (ADCs) Shows Unprecedented Promise in Early-Stage...
